Sidoti Csr Comments on Assertio’s Q3 Earnings (NASDAQ:ASRT)

Assertio Holdings, Inc. (NASDAQ:ASRT) – Sidoti Csr lowered their Q3 2025 earnings per share estimates for Assertio in a research report issued on Thursday, March 13th. Sidoti Csr analyst J. Sidoti now forecasts that the company will post earnings per share of $0.00 for the quarter, down from their prior estimate of $0.02. The consensus estimate for Assertio’s current full-year earnings is ($0.15) per share. Sidoti Csr also issued estimates for Assertio’s Q4 2025 earnings at $0.00 EPS.

A number of other equities research analysts have also recently commented on ASRT. HC Wainwright reissued a “buy” rating and issued a $4.00 price objective on shares of Assertio in a research note on Monday, December 16th. StockNews.com cut Assertio from a “buy” rating to a “hold” rating in a research report on Monday.

Assertio Trading Up 1.0 %

Shares of Assertio stock opened at $0.73 on Monday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.57 and a current ratio of 2.01. Assertio has a 52 week low of $0.68 and a 52 week high of $1.80. The stock has a 50 day moving average price of $0.81 and a two-hundred day moving average price of $0.96. The stock has a market capitalization of $69.63 million, a PE ratio of -1.00, a price-to-earnings-growth ratio of 3.25 and a beta of 0.81.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Two Sigma Investments LP boosted its position in shares of Assertio by 3.9% during the fourth quarter. Two Sigma Investments LP now owns 910,046 shares of the company’s stock valued at $793,000 after buying an additional 34,004 shares during the last quarter. Northern Trust Corp boosted its position in shares of Assertio by 21.3% during the fourth quarter. Northern Trust Corp now owns 227,217 shares of the company’s stock valued at $198,000 after buying an additional 39,906 shares during the last quarter. Stifel Financial Corp bought a new stake in Assertio during the fourth quarter worth $27,000. Marshall Wace LLP bought a new stake in Assertio during the fourth quarter worth $64,000. Finally, Geode Capital Management LLC lifted its holdings in Assertio by 2.0% during the fourth quarter. Geode Capital Management LLC now owns 1,095,911 shares of the company’s stock worth $955,000 after acquiring an additional 21,059 shares during the period. Hedge funds and other institutional investors own 48.96% of the company’s stock.

About Assertio

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.